Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Consumer Health Care Products Industry Earnings Roundup

This article was originally published in The Tan Sheet

Executive Summary

Pfizer Likes Consumer, But Not U.S. Tax Policy; Consumer Segment Stays At Reckitt, Rx To Leave; Merck Consumer Brands Strong With Division Sale Pending; Exchange Rates Deflate Bayer Growth; No Buyer’s Remorse At Sanofi; and Gummy Vitamin Business Soars For C&D

You may also be interested in...



RB Starts ‘Supercharge’ Diet To Be ‘Leaner, More Agile’ In Consumer Health

RB expects its “supercharge” cost-cutting strategy to yield as much as $228.5 million in annualized cost savings. The Mucinex marketer also says by 2020 it should compete almost exclusively in the consumer health, personal and household care markets.

RB Starts ‘Supercharge’ Diet To Be ‘Leaner, More Agile’ In Consumer Health

RB expects its “supercharge” cost-cutting strategy to yield as much as $228.5 million in annualized cost savings. The Mucinex marketer also says by 2020 it should compete almost exclusively in the consumer health, personal and household care markets.

RB Consumer Provides Bright Spot In Dim Quarter Despite Slower Sales

RB missed analysts third-quarter expectations by 1%, reporting a 2% sales increase to $3.82 billion. Consumer health product sales led the way with a 6% increase to $1.21 billion, dragged down slightly by slower than expected uptake of Mucinex and MegaRed products.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS107069

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel